{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T01:27:25Z","timestamp":1786670845355,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Care Fundation Chirec"},{"DOI":"10.13039\/501100011091","name":"Belgian Federal Public Service \u2018Health, Food Chain Safety, and Environment","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011091","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000805","name":"European Centre for Disease Prevention and Control","doi-asserted-by":"publisher","award":["Framework Contract ECDC\/2021\/016 (VEBIS project)"],"award-info":[{"award-number":["Framework Contract ECDC\/2021\/016 (VEBIS project)"]}],"id":[{"id":"10.13039\/501100000805","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Union (BE-SURVID project)."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13419-y","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T11:47:27Z","timestamp":1779277647000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["National real-life impact of prevention with nirsevimab on infants\u2019 RSV hospitalizations in Belgium"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4460-3420","authenticated-orcid":false,"given":"Sophie","family":"Blumental","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Lajot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathil","family":"Vandromme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Lafort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinthe","family":"Dockx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Denayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Wampers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Nebbioso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Tilmanne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Mignon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Tuerlinckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne","family":"Rigolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Matthijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Vandersnickt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Hellinckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Dewulf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrien","family":"Coppens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Van Hoorenbeeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen","family":"Vanlede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lore","family":"Winters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Seyler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Pierre","family":"Parsy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijke","family":"Reynders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Balcaen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montse","family":"Urbina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Dauby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Chatzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinout","family":"Naesens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Dorval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Ternest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Vanspeybroeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Goetghebuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tine","family":"Van Ackere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valbona","family":"Selimaj Kontoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wassim","family":"El Bitar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Holemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yveline","family":"Bruyere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan","family":"Van Brusselen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurane","family":"De Mot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Raes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"key":"13419_CR1","doi-asserted-by":"publisher","unstructured":"Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047\u20132064. https:\/\/doi.org\/10.1016\/s0140-6736(22)00478-0.","DOI":"10.1016\/s0140-6736(22)00478-0"},{"key":"13419_CR2","doi-asserted-by":"publisher","unstructured":"Shi T, McAllister DA, O\u2019Brien KL, Simoes EAF, Madhi SA, Gessner BD, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946\u2013958. https:\/\/doi.org\/10.1016\/s0140-6736(17)30938-8.","DOI":"10.1016\/s0140-6736(17)30938-8"},{"key":"13419_CR3","doi-asserted-by":"publisher","unstructured":"Linssen RS, Teirlinck AC, van Boven M, Biarent D, Stona L, Amigoni A, et al. Increasing burden of viral bronchiolitis in the pediatric intensive care unit: an observational study. J Crit Care. 2022;68:165\u2013168. https:\/\/doi.org\/10.1016\/j.jcrc.2021.07.009.","DOI":"10.1016\/j.jcrc.2021.07.009"},{"key":"13419_CR4","doi-asserted-by":"publisher","unstructured":"Dallagiacoma G, Rhedin SA, Odone A, Alfv\u00e9n T. A comparative analysis of non-pharmaceutical interventions for preventing respiratory syncytial virus in 30 European countries. Acta Paediatr. 2024;113(6):1388\u20131395. https:\/\/doi.org\/10.1111\/apa.17199.","DOI":"10.1111\/apa.17199"},{"key":"13419_CR5","unstructured":"EMA. Beyfortus (nirsevimab). EMA\/394366\/2024. Amsterdam: EMA; 2022 [updated 2024 Sep 4; cited 2025 Nov 28]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/beyfortus-epar-medicine-overview_en.pdf"},{"key":"13419_CR6","unstructured":"EMA. Abrysvo (respiratory syncytial virus vaccine [bivalent, recombinant]). EMA\/80045\/2025. Amsterdam: EMA; 2023 [updated 2025 Apr 11; cited 2025 Nov 28]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/abrysvo-epar-medicine-overview_en.pdf"},{"key":"13419_CR7","doi-asserted-by":"publisher","unstructured":"Sanchez-Martinez A, Moore T, Freitas TS, Benzaken TR, O\u2019Hagan S, Millar E, et al. Recent advances in the prevention and treatment of respiratory syncytial virus disease. J Gen Virol. 2025;106(4). https:\/\/doi.org\/10.1099\/jgv.0.002095.","DOI":"10.1099\/jgv.0.002095"},{"key":"13419_CR8","doi-asserted-by":"publisher","unstructured":"Saif-Ur-Rahman KM, King C, Whelan SO, Blair M, Donohue S, Madden C, et al. Efficacy and safety of respiratory syncytial virus vaccines. Cochrane Database Syst Rev. 2025;9(9):CD016131. https:\/\/doi.org\/10.1002\/14651858.CD016131.","DOI":"10.1002\/14651858.CD016131"},{"key":"13419_CR9","doi-asserted-by":"publisher","unstructured":"Sumsuzzman DM, Wang Z, Langley JM, Moghadas SM. Real-world effectiveness of nirsevimab against respiratory syncytial virus disease in infants: a systematic review and meta-analysis. Lancet Child Adolesc Health. 2025;9(6):393\u2013403. https:\/\/doi.org\/10.1016\/S2352-4642(25)00093-8.","DOI":"10.1016\/S2352-4642(25)00093-8"},{"key":"13419_CR10","doi-asserted-by":"publisher","unstructured":"Nunez O, Olmedo C, Moreno-Perez D, Lorusso N, Fernandez Martinez S, Pastor Villalba PE, et al. Effectiveness of catch-up and at-birth nirsevimab immunisation against RSV hospital admission in the first year of life: a population-based case-control study, Spain, 2023\/24 season. Euro Surveill. 2025;30(5). https:\/\/doi.org\/10.2807\/1560-7917.ES.2025.30.5.2400596.","DOI":"10.2807\/1560-7917.ES.2025.30.5.2400596"},{"key":"13419_CR11","doi-asserted-by":"publisher","unstructured":"Assad Z, Romain AS, Aupiais C, Shum M, Schrimpf C, Lorrot M, et al. Nirsevimab and hospitalization for RSV bronchiolitis. N Engl J Med. 2024;391(2):144\u2013154. https:\/\/doi.org\/10.1056\/NEJMoa2314885.","DOI":"10.1056\/NEJMoa2314885"},{"key":"13419_CR12","doi-asserted-by":"publisher","unstructured":"Moline HL, Tannis A, Toepfer AP, Williams JV, Boom JA, Englund JA, et al. Early estimate of nirsevimab effectiveness for prevention of respiratory syncytial virus\u2013associated hospitalization among infants entering their first RSV season\u2014New Vaccine Surveillance Network, October 2023\u2013February 2024. MMWR Morb Mortal Wkly Rep. 2024;73(9):209\u2013214. https:\/\/doi.org\/10.15585\/mmwr.mm7309a4.","DOI":"10.15585\/mmwr.mm7309a4"},{"key":"13419_CR13","doi-asserted-by":"publisher","unstructured":"Hsiao A, Hansen J, Fireman B, Timbol J, Zerbo O, Mari K, et al. Effectiveness of nirsevimab against RSV and RSV-related events in infants. Pediatrics. 2025;156(2). https:\/\/doi.org\/10.1542\/peds.2024-069510.","DOI":"10.1542\/peds.2024-069510"},{"key":"13419_CR14","doi-asserted-by":"publisher","unstructured":"Ernst C, Bejko D, Gaasch L, Hannelas E, Kahn I, Pierron C, et al. Impact of nirsevimab prophylaxis on paediatric RSV-related hospitalisations during the initial 2023\/24 season in Luxembourg. Euro Surveill. 2024;29(4). https:\/\/doi.org\/10.2807\/1560-7917.ES.2024.29.4.2400033.","DOI":"10.2807\/1560-7917.ES.2024.29.4.2400033"},{"issue":"10","key":"13419_CR15","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1097\/INF.0000000000004038","volume":"42","author":"N Bouckaert","year":"2023","unstructured":"Bouckaert N, Lefevre M, Van den Heede K, Van de Voorde C. RSV burden and its impact on pediatric inpatient bed occupancy in Belgium: an analysis of national hospital claims data. Pediatr Infect Dis J. 2023;42(10):857\u201361. https:\/\/doi.org\/10.1097\/INF.0000000000004038.","journal-title":"Pediatr Infect Dis J"},{"key":"13419_CR16","unstructured":"Li X, Roberfroid D, Bilcke J, Castanares-Zapatero D, De Meester C, Mao Z, et al. Cost-effectiveness of Abrysvo\u00ae and Beyfortus\u00ae against RSV infections in Belgian infants. Brussels: Belgian Health Care Knowledge Centre (KCE); 2025 [cited 2025 Nov 28]. KCE Reports 402. Available from: https:\/\/kce.fgov.be\/sites\/default\/files\/2025-06\/KCE_402_RSV_Infections_Belgian_Infants_Report.pdf"},{"key":"13419_CR17","unstructured":"Superior Health Council. Preventive strategies against RSV disease in children. Brussels: Superior Health Council; 2023 [cited 2025 Nov 28]. Available from: https:\/\/www.hgr-css.be\/file\/download\/5a601d75-1103-41f7-b532-3aeafe3630bc\/v5Bss4Qb97dpaGKtiuGmIn5TmeT8ghloMfitqR6aI3d.pdf"},{"key":"13419_CR18","doi-asserted-by":"publisher","unstructured":"Fischer N, Dauby N, Bossuyt N, Reynders M, Gerard M, Lacor P, et al. Monitoring of human coronaviruses in Belgian primary care and hospitals, 2015\u201320: a surveillance study. Lancet Microbe. 2021;2(3):e105\u2013e114. https:\/\/doi.org\/10.1016\/S2666-5247(20)30221-4.","DOI":"10.1016\/S2666-5247(20)30221-4"},{"key":"13419_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/S26665247(20)30221-4","author":"N Fischer","year":"2021","unstructured":"Fischer N, Dauby N, Bossuyt N, et al. Monitoring of human coronaviruses in Belgian primary care and hospitals, 2015\u201320: a surveillance study. Lancet Microbe. 2021. https:\/\/doi.org\/10.1016\/S26665247(20)30221-4. published online January 27.","journal-title":"Lancet Microbe"},{"issue":"7","key":"13419_CR20","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1093\/jac\/dkaf123","volume":"80","author":"SF Hak","year":"2025","unstructured":"Hak SF, Venekamp RP, Billard MN, Cianci D, Van Houten MA, Pollard AJ, et al. Antibiotic use attributable to RSV infections during infancy-an international prospective birth cohort study. J Antimicrob Chemother. 2025;80(7):1803\u201312. https:\/\/doi.org\/10.1093\/jac\/dkaf123.","journal-title":"J Antimicrob Chemother"},{"key":"13419_CR21","doi-asserted-by":"publisher","unstructured":"Fierens S, Brugerolles C, Lafort Y, Vandromme M, Mpakaniye P, Lajot A, et al. Surveillance des infections respiratoires aigu\u00ebs: rapport \u00e9pid\u00e9miologique saison 2024\u20132025. Brussels: Sciensano; 2025. https:\/\/doi.org\/10.25608\/rfed-t97","DOI":"10.25608\/rfed-t97"},{"key":"13419_CR22","doi-asserted-by":"publisher","unstructured":"erramon-Malavez A, Buonsenso D, Morello R, Coma E, Foster S, Leonard P, et al. Real-world impact of nirsevimab immunisation against respiratory disease on emergency department attendances and admissions among infants: a multinational retrospective analysis. Lancet Reg Health Eur. 2025;55:101334. https:\/\/doi.org\/10.1016\/j.lanepe.2025.101334.","DOI":"10.1016\/j.lanepe.2025.101334"},{"key":"13419_CR23","doi-asserted-by":"publisher","unstructured":"Savulescu C, Ganser I, Nicolay N, Lajot A, Campos S, Martinez-Baz I, et al. Effectiveness of long-acting monoclonal antibodies against laboratory-confirmed RSV in children aged <24 months and hospitalised for severe acute respiratory infection. Euro Surveill. 2025;30(45):2500816. https:\/\/doi.org\/10.2807\/1560-7917.","DOI":"10.2807\/1560-7917"},{"key":"13419_CR24","doi-asserted-by":"publisher","unstructured":"Sankatsing VDV, Hak SF, Wildenbeest JG, Venekamp RP, Pistello M, Rizzo C, et al. Economic impact of RSV infections in young children attending primary care: a prospective cohort study in five European countries, 2021 to 2023. Euro Surveill. 2025;30(20):2400797. https:\/\/doi.org\/10.2807\/1560-7917.ES.2025.30.20.2400797","DOI":"10.2807\/1560-7917.ES.2025.30.20.2400797"},{"key":"13419_CR25","doi-asserted-by":"publisher","unstructured":"Madhi SA, Ceballos A, Cousin L, Domachowske JB, Langley JM, Lu E, et al. Population attributable risk of wheeze in 2\u2013<6-year-old children following RSV lower respiratory tract infection in the first 2 years of life. Pediatr Infect Dis J. 2025;44(5):379\u2013386. https:\/\/doi.org\/10.1097\/INF.0000000000004447.","DOI":"10.1097\/INF.0000000000004447"},{"issue":"4","key":"13419_CR26","first-page":"255","volume":"26","author":"S Blumental","year":"2024","unstructured":"Blumental S, Grossman D. Acceptability of new RSV preventive tools to parents and healthcare workers. Belg J Paediatr. 2024;26(4):255\u201357.","journal-title":"Belg J Paediatr"},{"issue":"1","key":"13419_CR27","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00431-022-04698-z","volume":"182","author":"M Raes","year":"2023","unstructured":"Raes M, Daelemans S, Cornette L, Moniotte S, Proesmans M, Schaballie H, et al. The burden and surveillance of RSV disease in young children in Belgium-expert opinion. Eur J Pediatr. 2023;182(1):451\u201360. https:\/\/doi.org\/10.1007\/s00431-022-04698-z.","journal-title":"Eur J Pediatr"},{"key":"13419_CR28","unstructured":"Broberg E. EU case definitions for respiratory viruses. Stockholm: European Centre for Disease Prevention and Control; 2024 [cited 2025 Nov 28]. https:\/\/www.ecdc.europa.eu\/en\/news-events\/respiratory-virus-network-meeting-2024"},{"key":"13419_CR29","doi-asserted-by":"publisher","unstructured":"Macina D, Evans KE. Bordetella pertussis in school-age children, adolescents and adults: a systematic review of epidemiology and mortality in Europe. Infect Dis Ther. 2021;10(4):2071\u20132118. https:\/\/doi.org\/10.1007\/s40121-021-00520-9.","DOI":"10.1007\/s40121-021-00520-9"},{"issue":"4","key":"13419_CR30","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1093\/infdis\/jiy189","volume":"218","author":"Q Zhu","year":"2018","unstructured":"Zhu Q, Lu B, McTamney P, Palaszynski S, Diallo S, Ren K, et al. Prevalence and significance of substitutions in the fusion protein of respiratory syncytial virus resulting in neutralization Escape from antibody MEDI8897. J Infect Dis. 2018;218(4):572\u201380. https:\/\/doi.org\/10.1093\/infdis\/jiy189.","journal-title":"J Infect Dis"},{"key":"13419_CR31","doi-asserted-by":"publisher","unstructured":"Stobbelaar K, Mangodt TC, Van der Gucht W, Delhaise L, Andries J, Gille V, et al. Risk factors associated with severe RSV infection in infants: what is the role of viral co-infections? Microbiol Spectr. 2023;11(3):e0436822. https:\/\/doi.org\/10.1128\/spectrum.04368-22.","DOI":"10.1128\/spectrum.04368-22"},{"key":"13419_CR32","doi-asserted-by":"publisher","unstructured":"Arbetter D, Gopalakrishnan V, Aksyuk AA, Ahani B, Chang Y, Dagan R, et al. Lower respiratory tract infections following RSV monoclonal antibody nirsevimab immunization versus placebo: analysis from a phase 3 randomized clinical trial (MELODY). Clin Infect Dis. 2025;81(3):634\u2013644. https:\/\/doi.org\/10.1093\/cid\/ciae596.","DOI":"10.1093\/cid\/ciae596"},{"key":"13419_CR33","doi-asserted-by":"publisher","unstructured":"Rius-Peris JM, Palomo-Atance E, Muro-D\u00edaz E, Llorente-Ruiz C, Murcia-Clemente L, Alcaraz R. Nirsevimab immunisation significantly reduces RSV-associated bronchiolitis hospitalisations and alters seasonal patterns. Acta Paediatr. 2025;114(8):1963\u20131976. https:\/\/doi.org\/10.1111\/apa.70066.","DOI":"10.1111\/apa.70066"},{"key":"13419_CR34","doi-asserted-by":"publisher","unstructured":"Hetrich MK, Oliva J, Wanionek K, Knoll MD, Lamore M, Esteban I, et al. Epidemiology of human parainfluenza virus type 3 and RSV infections in the time of COVID-19: findings from a household cohort in Maryland. Clin Infect Dis. 2023;76(8):1349\u20131357. https:\/\/doi.org\/10.1093\/cid\/ciac942.","DOI":"10.1093\/cid\/ciac942"},{"key":"13419_CR35","unstructured":"WHO. World report on social determinants of health equity, 2025. Geneva: WHO; 2025 [cited 2025 Nov 28]. https:\/\/www.who.int\/teams\/social-determinants-of-health\/equity-and-health\/world-report-on-social-determinants-of-health-equity"},{"issue":"3","key":"13419_CR36","first-page":"186","volume":"26","author":"G Nikitas","year":"2024","unstructured":"Nikitas G, Allmon AG, Meulemans A, Billiaert K, Strubbe F, Magis D, et al. Regional inequity in 4CMebB vaccination coverage in Belgium: a retrospective ecological study. Belg J Paediatr. 2024;26(3):186\u201392.","journal-title":"Belg J Paediatr"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13419-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13419-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13419-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:47:58Z","timestamp":1786668478000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13419-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13419"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13419-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"21 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Both study protocols were approved by ethics committees of participating hospitals. For the SARI surveillance, approval from a coordinating central ethical committee was also obtained (Ref: B.U.N. 143201215671). No informed consent was requested for the RSV Ped survey due to its retrospective design. The whole study was conducted in compliance with the principles of GCP and in accordance with all applicable regulatory requirements.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable (no identifying images or other personal or clinical details of participants that compromise anonymity in our survey).","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ChatGPT was used to generate portions of the code for data management and statistical analysis (R Software). After using this tool, AL reviewed and edited the content as needed and takes full responsibility for the final version of the article.","order":3,"name":"Ethics","label":"Use of AI","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AL, MV, YL, YD, SD, AW, AN, AT, CM, DT, HR, IM, JV, JH, JD, KC, KVH, KV, LW, MB, MP, MU, OC, SD, ST, SV, TV, VSK, XH, and YB have no conflict of interest to declare. SB has taken part to one advisory board of VIATRIS (outside the scope of this work) and has been speaker for Mediquality. MR and TG have received honoraria from Sanofi, MSD and GSK for taking part in advisory boards and expert meetings and for acting as a speaker in congresses. DVB has received honoraria from Sanofi, MSD and Pfizer for taking part in advisory boards and expert meetings. TG has been clinical investigator in a nirsevimab clinical trial. N.D had honoraria from MSD for advisory board; speaker fees from Abbvie, Mediquality and Astra Zeneca (outside the scope of this work), travel fees and research grant from MSD. travel fees from Gilead and ViiV Healthcare, WEB is MSD global international speaker outside of the scope of the submitted work and participated to MSD EMA HPV advisory board. MRE has received travel grant from Pfizer.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1494"}}